H., Fischer, H., Ard, J.,et al
GLP-1RA Offers Added Protection in Lupus GLP-1 receptor agonists are already well-established for their cardioprotective and kidney-protective effects in T2D, but their potential benefit in high-risk autoimmune populations has been less clear
After 24 weeks of treatment, significant reductions in neuropathy symptom and disability scores and in neurophysiological parameters were seen in both groups, with no difference between the two drugs safety-wise
Willow offers GLP-1 medications, including Semaglutide and Tirzepatide, when determined by a doctor to be medically appropriate
This neuroimmune activation can manifest as brain fog, fatigue, anxiety, insomnia, and chemical sensitivity, even in patients who appear outwardly healthy